Curis, Inc. (NASDAQ:CRIS) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 189,000 shares, a decline of 49.0% from the October 31st total of 370,800 shares. Based on an average daily volume of 150,300 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.7% of the shares of the stock are short sold.
NASDAQ:CRIS traded up $0.02 during trading hours on Wednesday, hitting $1.79. 216,150 shares of the company traded hands, compared to its average volume of 307,744. Curis has a twelve month low of $0.60 and a twelve month high of $2.90. The firm has a 50-day moving average of $1.86 and a 200 day moving average of $1.92.
Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $2.86 million for the quarter.
Several hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC acquired a new position in shares of Curis in the 3rd quarter valued at $2,781,000. Renaissance Technologies LLC grew its holdings in shares of Curis by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,191,419 shares of the biotechnology company’s stock worth $2,216,000 after purchasing an additional 203,590 shares during the last quarter. Fosun International Ltd grew its holdings in shares of Curis by 46.6% in the 2nd quarter. Fosun International Ltd now owns 581,834 shares of the biotechnology company’s stock worth $1,065,000 after purchasing an additional 184,965 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Curis by 15.2% in the 2nd quarter. BlackRock Inc. now owns 487,816 shares of the biotechnology company’s stock worth $908,000 after purchasing an additional 64,262 shares during the last quarter. Finally, BB&T Securities LLC grew its holdings in shares of Curis by 131.6% in the 3rd quarter. BB&T Securities LLC now owns 43,994 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 26.32% of the company’s stock.
Curis Company Profile
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Featured Story: What are the disadvantages of after-hours trading?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.